CYP2A6 CRISPR/Cas9 KO Plasmid (h): sc-403448
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2A6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP2A6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2A6 CRISPR/Cas9 KO Plasmid (h) | sc-403448 | 20 µg | $397.00 |
Overview
CYP2A6 encodes a human cytochrome P450 monooxygenase that catalyzes oxidative metabolism of a range of xenobiotics and select endogenous substrates, contributing to cellular chemical homeostasis and redox balance. As an endoplasmic reticulum–localized hemoprotein, CYP2A6 functions within phase I drug metabolism pathways and cooperates with NADPH–cytochrome P450 reductase to support electron transfer during substrate oxidation. Variation in CYP2A6 expression or activity can shift metabolic flux and influence susceptibility to chemically induced toxicity and carcinogen activation, making it relevant to studies of pharmacogenomic diversity and exposure-related disease mechanisms. Its hepatic enrichment and inducible regulation also support investigation of transcriptional control, enzyme stability, and adaptive responses to environmental chemicals.
CYP2A6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP2A6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP2A6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP2A6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP2A6 protein expression.
This CRISPR knockout system enables efficient generation of CYP2A6-deficient cell models for investigation of CYP2A6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP2A6 exon(s) critical for CYP2A6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP2A6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP2A6 CRISPR/Cas9 KO Plasmid (h) and CYP2A6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP2A6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP2A6 HDR Plasmid (h) and CYP2A6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP2A6 homology arms to support homology-directed repair at defined CYP2A6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.